GILD.TO Gilead Sciences CDR (CAD Hedged)
- Market cap
- -
- P/E
- -
- P/B
- 15.29x
- ROE
- -61.8%
- Dividend yield
- 1.62%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is GILD.TO undervalued?
Graham numberThe Graham number of Gilead Sciences CDR (CAD Hedged) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Gilead Sciences CDR (CAD Hedged) fundamental analysis
No fundamental analysis for Gilead Sciences CDR (CAD Hedged) yet.
Gilead Sciences CDR (CAD Hedged) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Gilead Sciences CDR (CAD Hedged)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatmen…
Full company profileGilead Sciences CDR (CAD Hedged) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Gilead Sciences CDR (CAD Hedged) annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 27.3B | 27.1B | 28.8B | 29.4B | 30.8B |
| Gross Profit | 21.6B | 21.1B | 22.5B | 23.2B | 24.6B |
| Operating Income | 7.33B | 7.61B | 1.66B | 10.0B | 11.6B |
| EBITDA | 8.85B | 10.5B | 4.43B | 13.6B | -2.30B |
| Net Income | 4.59B | 5.66B | 479M | 8.51B | -8.06B |
| EPS | 3.68 | 4.55 | 0.38 | 6.86 | -6.50 |
| Balance Sheet | |||||
| Total Assets | 63.2B | 62.1B | 59.0B | 59.0B | 51.4B |
| Total Liabilities | 41.9B | 39.3B | 39.7B | 36.3B | 38.5B |
| Shareholders' Equity | 21.2B | 22.8B | 19.3B | 22.7B | 13.0B |
| Cash & Short-term Investments | 6.39B | 7.26B | 9.99B | 7.63B | 6.44B |
| Cash Flow | |||||
| Operating Cash Flow | 9.07B | 8.01B | 10.8B | 10.0B | 14.9B |
| Capital Expenditure | 728M | 585M | 523M | 563M | 659M |
| Free Cash Flow | 8.34B | 7.42B | 10.3B | 9.46B | 14.2B |
| Ratios | |||||
| ROE | 21.6% | 24.8% | 2.5% | 37.5% | -61.8% |
| ROA | 7.3% | 9.1% | 0.8% | 14.4% | -15.7% |
| Net Profit Margin | 16.8% | 20.9% | 1.7% | 28.9% | -26.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Gilead Sciences CDR (CAD Hedged) dividends
- Dividend yield
- 1.62%
- Forward dividend
- -
- Payout ratio
- 47.0%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 4.00B | 3.23 | 47.0% |
| 2024 | USD 3.92B | 3.14 | 818.0% |
| 2023 | USD 3.81B | 3.06 | 67.2% |
| 2022 | USD 3.71B | 2.97 | 80.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Gilead Sciences CDR (CAD Hedged)
Ownership data of Gilead Sciences CDR (CAD Hedged) is not available yet.
Gilead Sciences CDR (CAD Hedged) company profile
- Company name
- Gilead Sciences CDR (CAD Hedged)
- Ticker
- GILD.TO
- Exchange
- Toronto Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 17,600
- Fiscal year end
- December
- Address
- 333 Lakeside Drive, Foster City, CA, United States, 94404
- Phone
- 650 574 3000
- Website
- gilead.com
About Gilead Sciences CDR (CAD Hedged)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences CDR (CAD Hedged) management
10- Mr. Daniel P. O'DayChairman & CEO · born 1965
- Mr. Andrew D. DickinsonChief Financial Officer · born 1970
- Ms. Johanna MercierChief Commercial Officer · born 1970
- Ms. Erin BurkhartSVP, Controller & Principal Accounting Officer · born 1979
- Ms. Jacquie Ross C.F.A.Senior Vice President of Treasury and Investor Relations
- Ms. Keeley WettanExecutive VP and General Counsel of Legal & Compliance
- Ms. Jyoti K. MehraExecutive Vice President of Human Resources · born 1976
- Dr. Linda Slanec Higgins Ph.D.Senior Vice President of Research, Innovation & Portfolio · born 1962
- Dr. Flavius Martin M.D.Executive Vice President of Research
- Ms. Janet DorlingSenior Vice President of Intercontinental Region & Global Patient Solutions · born 1974